Inhaled Dry Powder CBD For Epileptic Seizures: Receptor Life Sciences' FDA Drug Application
UCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The Highlights
Inhaled Dry Powder CBD For Epileptic Seizures: Receptor Life Sciences' FDA Drug Application
UCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The Highlights
Study Suggests Whole-Plant Medicinal Cannabis Could Be More Effective Than CBD In Epilepsy Treatment
Taysha Gene's Epilepsy Candidate Shows Encouraging Action In Preclinical Studies
Study Suggests Whole-Plant Medicinal Cannabis Could Be More Effective Than CBD In Epilepsy Treatment
Taysha Gene's Epilepsy Candidate Shows Encouraging Action In Preclinical Studies
Stoke Touts Early Signs Of Efficacy For Antisense Drug In Dravet Syndrome
Xenon Stock Jumps On New Encouraging Data From Epilepsy Treatment
Epilepsy Recent News
Xenon Pharma Shares Jump After Epilepsy Treatment Phase 2 Data Meets Primary Endpoint
Taysha's Rare Epilepsy Gene Therapy Receives European Orphan Drug Tag
UK Competition And Markets Authority Accuses Pfizer Of Illegal Pricing Of Its Epilepsy Drug
Marinus Files US Application For Ganaxolone For Genetic Epilepsy, Inks European Commercialization Pact With Orion
OPKO Health, CAMP4 Therapeutics Ink Oligonucleotide Platform With Focus On Drug-Resistant Epilepsy
Zynerba's Zygel Improves Sleep In Children With Severe Epilepsies
Zogenix's Fintepla Associated With Improvements in Seizure Control, Executive Functions In Childhood Epilepsy Disorder
Ovid Shares Rally On Soticlestat Development Pact With Takeda In Rare Epilepsy Syndromes
How Can Cannabis Help With Epilepsy?
'Exceeded Our Expectations': First Latin American Study On CBD, Epilepsy Completed
'Renewed Sense Of Hope': GW Pharma CEO Talks Epilepsy Drug Approval In Europe
Zogenix Soars On Positive Phase 3 Data In Dravet Syndrome Study
GW Pharmaceuticals' FDA Win Reinforces BofA's Bullish Thesis
Marinus Pharmaceuticals Has 3 Major Catalysts In 2018, Ladenburg Thalmann Says In Bullish Initiation
'An Incredible Signal': 4 Experts Weigh In On Positive FDA Panel Vote For GW Pharma's Epidiolex
Zynerba Pharmaceuticals Shares Volatile After Epilepsy Study Results
What Do Zogenix Drug Study Results Mean For GW Pharmaceuticals' Epidiolex?
What's The Difference Between Zynerba and GW Pharma's Epilepsy Drugs?
What Analysts Expect For Zynerba's Upcoming Wave Of Data
Pfizer Fined $106 Million For Anti-Epilepsy Drug
Oppenheimer Downgrades Marinus Pharmaceuticals, Removes Price Target On Disappointing Epilepsy Study Results
Supernus Pharma Should Have More Strength After Epilepsy Drug Patent Decision, Northland's Buck Says
Edible Marijuana Products Get The 'Okay' In Canada